{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/89574d00\"></iframe>","width":"100%","height":180,"duration":2603,"description":"In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. \nHere are the trials we discussed: \n1. IWG 2019 response criteria\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ \n2. MEDALIST trial: Luspatercept\nhttps://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed \n3. COMMANDS trial : Luspatercept \nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract\nhttps://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract \n4. IMerge trial: Imetelstat \nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract\n \n ","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}